- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Barrier takes second dermatologic product into Canada
Princeton, N.J.--Barrier Therapeutics Inc., a pharmaceutical company that specializes in dermatologic products, is now marketing and selling Vaniqa Cream (SkinMedica) in Canada.
Princeton, N.J.-Barrier Therapeutics Inc., a pharmaceutical company that specializes in dermatologic products, is now marketing and selling Vaniqa Cream (SkinMedica) in Canada.
Vaniqa (eflornithine hydrochloride) is a topical prescription product used for slowing the growth of excessive facial hair in women. It has been approved for such use by Health Canada. Princeton-based Barrier acquired the exclusive rights to distribute Vaniqa in Canada from Shire Pharmaceutical Contracts Ltd. in June.
Barrier also sells and markets another product, Solagé Topical Solution (Galderma) for age spots, in Canada.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
